

MusclePharm Corp  
Form 8-K  
March 15, 2017

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**March 15, 2017**

**Date of report (date of earliest event reported)**

**MusclePharm Corporation**

**(Exact name of registrant as specified in its charter)**

<b>Nevada</b>	<b>000-53166</b>	<b>77-0664193</b>
<b>(State or other jurisdictions of incorporation or organization)</b>	<b>(Commission File Number)</b>	<b>(I.R.S. Employer Identification Nos.)</b>

**4721 Ironton Street, Building A**

**Denver, Colorado 80239**

**(Address of principal executive offices) (Zip Code)**

**(303) 396-6100**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrants under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 7.01 REGULATION FD DISCLOSURE.**

On March 15, 2017, the Company issued a press release that included the Company's open letter to shareholders. A copy of the press release is attached to this report as Exhibit 99.1.

**Item 9.01. Exhibits**

(d)Exhibits

Exhibit No. Description

99.1 Shareholder Letter dated March 15, 2017.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MUSCLEPHARM  
CORPORATION**

By: /s/ Peter Lynch  
Name: Peter Lynch  
Title: Chief  
Financial Officer

Date: March 15, 2017

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Shareholder Letter dated March 15, 2017

